Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.
about
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysDapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion InjuryMechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusSodium glucose cotransporter 2 inhibition in the diabetic kidney: an updatePredicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.Recent advances in renal hypoxia: insights from bench experiments and computer simulations.Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy.Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.SGLT2 Inhibition in a Kidney with Reduced Nephron Number: Modeling and Analysis of Solute Transport and Metabolism.Sweet Success? SGLT2 Inhibitors and Diabetes.Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia.Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity.New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
P2860
Q28072939-A6E86D05-E74A-4075-AEE0-9F4842096EDFQ28552482-44D2485A-833E-43E3-9905-6415071DF507Q33633674-ABE2C990-30C2-410A-8190-F5BE6E84AA24Q33871321-12279035-9073-41C7-931C-14CE049159BCQ36435496-C7B85C49-07F8-4DAF-B9A6-B663B6D81D95Q37072443-4F66AF9F-B3F7-4DD1-AC5E-A66A0E03B676Q37139470-90981D9B-8D4F-4792-B361-95E5A1B66F53Q38607632-2DC6E5EA-F6EA-48A1-833E-224DD0008957Q39017610-7E92CA67-7A51-4772-8B5D-FF1C7F8E7846Q39300236-71CD6865-8FBF-4ADA-B680-DDA0A89CE419Q40799248-7887AC5A-3AE5-4B38-80F7-9CF8F065A574Q47103818-5152A859-8316-46ED-AC95-3AF48908E49AQ47557423-416523C1-5455-48E3-85A0-1EAF373E724BQ47557951-AB869F46-C26D-4DC6-AC55-4E7115441564Q47915074-CB222359-B86D-4622-A775-4A85A8345F18Q48130954-76C85DE2-AEE4-4D8C-A77D-74F273132A78Q50103024-B9D05072-4C5E-48AF-A78E-9179ADEA1F91Q50930999-BD904177-F2BB-46E8-AE0B-D6C6D352A532Q51733588-AAF15CC3-98DF-4A59-8A88-12C4433DFC5AQ51746289-143DD69C-04A2-464F-B369-B680ADBDBA47Q52671440-743473F7-268C-4A4A-A039-72A424C6EE4DQ52724494-A81E7207-33F9-40DF-BD16-31103C2BCFE5Q55174679-9898570F-2825-4912-B336-E2D3FF084B51Q55262124-C33D1534-956B-4B52-ABCD-2EC747FA3F0EQ55332339-53B600F3-98F4-4B4D-9BFA-8A24671D7B6E
P2860
Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Acute SGLT inhibition normaliz ...... zed control and diabetic rats.
@en
type
label
Acute SGLT inhibition normaliz ...... zed control and diabetic rats.
@en
prefLabel
Acute SGLT inhibition normaliz ...... zed control and diabetic rats.
@en
P2093
P2860
P1476
Acute SGLT inhibition normaliz ...... ized control and diabetic rats
@en
P2093
Angelica Fasching
Fredrik Palm
Julie O'Neill
Liselotte Pihl
Stephanie Franzén
P2860
P304
P356
10.1152/AJPRENAL.00689.2014
P577
2015-06-03T00:00:00Z